The National Biosafety Authority has developed a guideline document for determining the regulatory process of genome editing techniques through broad stakeholder consultations and review of regulatory mechanisms in other countries where such technology has been deployed.

The document incorporates the aspects of implementation, as well as essential testing pathways and implementation strategies in the country, taking into consideration all the possible sociocultural and ethical issues. This document is not meant to detail how risk assessment and risk management of genome edited products will be conducted.